在胰腺癌中,瘤相关的三级淋巴体结构基因的预后影响和特征
Enkui Zhang1, Yongsu Ma1, Zonghao Liu1
1Department of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Journal of translational medicine
|March 11, 2025
概括
这项研究确定了基于瘤相关的三级淋巴体结构 (TA-TLS) 的三种胰腺管道腺癌 (PDAC) 亚型. 一个新的风险模型和TLS得分预测患者的结果,并增强PDAC的免疫治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 基因组学就是基因组学.
背景情况:
- 胰腺管腺癌 (PDAC) 是一种具有抑制性瘤微环境 (TME) 的侵袭性癌症,限制了免疫治疗的有效性.
- 三级淋巴体结构 (TLS) 与PDAC中更好的预后和免疫治疗反应有关.
- 了解PDAC中的TLS对于改善治疗结果至关重要.
研究的目的:
- 阐明PDAC中瘤相关TLS (TA-TLS) 基因的表达特征.
- 开发一个基于TLS基因的评分系统和PDAC患者的风险评估模型.
- 探索关键基因,如DNASE1L3在PDAC中的功能及其在免疫治疗中的潜力.
主要方法:
- 来自310名PDAC患者的综合转录和临床数据.
- 在TA-TLS基因上进行了共识聚类,以确定分子亚型.
- 使用ssGSEA进行TLS评分,LASSO回归用于风险模型构建,以及scRNA-seq用于免疫细胞分析.
- 使用独立队列,IHC和DNASE1L3.3.的功能分析验证的结果.
主要成果:
- 确定了三种不同的PDAC分子亚型,具有差异性预后和TME特征.
- 开发了一种经过验证的风险模型和TLS得分,有效地对患者进行分层并与生存相关联.
- 证明DNASE1L3过度表达抑制了PDAC细胞的增殖和迁移,可能增强免疫活性.
结论:
- 在PDAC中阐明的TA-TLS基因表达模式.
- 建立了一个强大的TLS评分系统和风险模型来预测患者的预后.
- 提供了关于DNASE1L3抗瘤机制的见解,支持开发针对PDAC的TLS向免疫治疗策略.
相关概念视频
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
01:21Cancer Survival Analysis
863
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
863